Publications by authors named "Mathieu Uhart"

Claim this Profile
I
Incidence and Burden of Respiratory Syncytial Virus-Associated Hospitalizations Among People 65 and Older in France: A National Hospital Database Study.
Stéphane Marot, Clarisse Demont, Théophile Cocherie, Miao Jiang, Charlotte Charpentier, Mathieu Uhart

Open Forum Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.
Amy Lee, Benjamin Davido, Ekkehard Beck, Clarisse Demont, Keya Joshi, Mathieu Uhart

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Vaccine Platforms-Novel Dimensions of Economic and Societal Value and Their Measurement.
Philip O Buck, Dumingu Aparna Gomes, Ekkehard Beck, Noam Kirson, Matthew Mattera, Mathieu Uhart

Vaccines (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating the burden of influenza-related and associated hospitalizations and deaths in France: An eight-season data study, 2010-2018.
Magali Lemaitre, Fayssoil Fouad, Fabrice Carrat, Pascal Crépey, Jacques Gaillat, Mathieu Uhart

Influenza Other Respir Viruses· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination coverage rates for Diphtheria, Tetanus, Poliomyelitis and Pertussis booster vaccination in France between 2013 and 2017: Learnings from an analysis of National Health System Real-World Data.
Clarisse Marchal, Manon Belhassen, Nicole Guiso, Flore Jacoud, Eric Van Ganse, Mathieu Uhart

Vaccine· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cervical cancer screening coverage, management of squamous intraepithelial lesions and related costs in France.
Yann de Rycke, Florence Tubach, Alexandre Lafourcade, Sylvie Guillo, Marie Dalichampt, Mathieu Uhart

PLoS One· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiological and economic burden of potentially HPV-related cancers in France.
Laurent Abramowitz, Jean Lacau Saint Guily, Micheline Moyal-Barracco, Christine Bergeron, Hélène Borne, Mathieu Uhart

PLoS One· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.
Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Mathieu Uhart

Cost Eff Resour Alloc· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of chance associated with sub-optimal HPV vaccination coverage rate in France.
Mathieu Uhart, Marjorie Adam, André Dahlab, Xavier Bresse

Papillomavirus Res· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany.
Nathalie Largeron, Karl Ulrich Petry, Jorge Jacob, Florence Bianic, Delphine Anger, Mathieu Uhart

Expert Rev Pharmacoecon Outcomes Res· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
Mathieu Uhart, Hélène Bricout, Emilie Clay, Nathalie Largeron

Hum Vaccin Immunother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older.
Juan Luis Lopez-Belmonte, Ramón Cisterna, Angel Gil de Miguel, Caroline Guilmet, Florence Bianic, Mathieu Uhart

J Med Econ· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Emmanuelle Préaud, Mathieu Uhart, Katharina Böhm, Pamela Aidelsburger, Delphine Anger

Hum Vaccin Immunother· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The humanistic, economic and societal burden of herpes zoster in Europe: a critical review.
Adam Gater, Mathieu Uhart, Rachael McCool, Emmanuelle Préaud

BMC Public Health· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of fluoroquinolone reduced dosage regimens in elderly patients by using pharmacokinetic modelling and Monte Carlo simulations.
Bertrand Leroy, Mathieu Uhart, Pascal Maire, Laurent Bourguignon

J Antimicrob Chemother· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.
Laurent Bourguignon, Michel Ducher, David Matanza, Nathalie Bleyzac, Mathieu Uhart

Fundam Clin Pharmacol· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis